JPMorgan Chase has given back ground since Tuesday's print, closing at $295.70 on Wednesday — down 3% on the week and 4.7% lower over the past month — as the post-earnings bounce fades and a broad pattern of executive selling hangs over the recovery story.
The insider angle is the dominant thread this week. Four senior executives — the heads of asset and wealth management, commercial banking, technology, and consumer banking — each sold between 3,000 and 6,600 shares on May 15, collectively raising nearly $6.5 million at prices around $298–$300. That follows a separate round of selling by the CFO, COO, and Chief Risk Officer on May 5. The 90-day net figure across the C-suite now runs to approximately $177 million in sales across 592,000 shares. These are not isolated portfolio moves. The breadth of the selling — spanning multiple divisions and two separate dates in a single fortnight — tells a consistent story about how management is treating the current price range.
Options positioning has drifted back toward neutral after the unusually low put/call ratio flagged in the previous two notes. The PCR is now at 1.07, roughly 0.7 standard deviations below its 20-day average of 1.09. That is no longer a bullish outlier. The sharp unwind in downside protection that characterised the week before the May 19 earnings release has partially reversed, and the reading now sits closer to the middle of its 52-week range (0.96 low, 1.38 high). Short interest tells a quiet story of its own: SI remains at 0.94% of the free float — essentially unchanged from last week's post-AGM level — and the borrow market remains completely unconstrained. Cost to borrow has fallen further to 0.22%, the lowest in the 30-day window, and availability is effectively unlimited. There is no short-side pressure building in the lending market.
The Street's view on valuation is mixed but not alarmed. The mean analyst price target is $342, implying roughly 16% upside from here — a gap that has widened as the stock has drifted lower through May. Analyst activity following the Q1 release in mid-April was uniformly constructive: multiple firms raised targets, with Evercore lifting to $340 and Piper Sandler moving to $345, both maintaining positive ratings. The most recent action in the dataset is from early May, so the consensus snapshot does not yet reflect any post-Q2-interim reaction. The P/E multiple has compressed slightly to 13.0x, down about 1 point over 30 days, while price-to-book has eased to 2.14x. Neither is stretched for a large-cap bank. The dividend score ranks in the 95th percentile of the ORTEX universe — a useful floor for long-only holders watching the stock drift. Among peers, Citigroup had the toughest week, off 5.1%, while Wells Fargo and Bank of America held up better, each down less than 1%. JPM's underperformance relative to its two closest peers is a notable feature of this week's tape.
The largest institutional holders — Vanguard at 9.9%, BlackRock at 7.8%, and State Street at 4.6% — all added modestly to their positions through April, which provides a degree of structural demand beneath the current price. But passive index buying is a slow-moving anchor, not a catalyst.
The next scheduled event is the Q2 earnings release on July 14. Between now and then, the more useful data point to track is whether the executive selling cluster extends into June — and whether the gap between the current price and the $342 consensus target begins to close or widen further as macro conditions develop through the summer.
See the live data behind this article on ORTEX.
Open JPM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
